Markets, explained.

Biotech Floods the August IPO Window While the SEC Rethinks 20 Years of Market Structure

Six biotech IPOs priced in the first week of August, and July's $29.3 billion in new listings was the busiest July in a decade. But the SEC's June proposal to rescind Regulation NMS Rule 611 could quietly reshape the plumbing underneath it all.

Two Oil Chokepoints Squeezed at Once: Hormuz at a Trickle, Senate Votes 100% Tariffs on Russian Oil Buyers

Iran's blockade of the Strait of Hormuz has cut tanker transits to a trickle while the Senate's Graham Act threatens 100% tariffs on the top five buyers of Russian oil. Two energy chokepoints under simultaneous pressure, a new regional military pact, and record equities — a divergence worth watching.

The Soft-Jobs Paradox: S&P 500 at a Record, but the Labor Market Just Cracked

The U.S. economy shed 23,000 jobs in July against expectations for 83,000 added. The S&P 500 closed at a fresh all-time high. Semiconductors, gold, and software led the rally while The Trade Desk cratered on its slowest revenue growth since 2020. The 30-year Treasury yield sits near a 19-year high.

Biotech IPOs Surge Into August as SpaceX Lockup Tests the Float

The August IPO window is opening wider than expected, with four biotechs raising $1.17 billion — all upsized. SpaceX's staggered lockup expiry could more than double the float, and the SEC's proposed rescission of Reg NMS Rule 611 looms as the most significant market-structure change in two decades.

S&P 500 Record Close Caps Best Week Since April as Jobs Miss Defuses Fed-Hike Risk

The Nasdaq's 5.2% weekly surge is one of the cleanest tells in the opening snapshot: a soft payrolls print eased rate-hike pressure just as Q2 earnings beats landed at record margins, lifting semiconductors and AI-software names while energy and financials lagged. The macro analog to 2006 suggests caution, not alarm.

Biotech Leads August's IPO Surge as Issuance Window Swings Wide Open

Six IPOs priced in the first week of August 2026 — four biotechs raising $1.17 billion combined — led by Braveheart Bio's 67% first-week pop. The issuance window is widening even as market-structure shifts reshape liquidity underneath new listings.

Hormuz Deal at One Signature: Oil Risk Premium Unwinds, But Refined-Product Squeeze Stays

Iran's security council is on the verge of approving a 60-day Hormuz deal that has already sent oil down 5% and the S&P 500 to record highs — but record diesel crack spreads and new polysilicon tariffs mean two supply-chain shocks are running at once.

Soft Jobs Report Hands Tech the Reins: Semis Surge, Energy Fades, and a 2006 Echo Looms

July payrolls fell 23,000 versus 80,000 expected, cooling rate-hike bets and handing the semiconductor and AI infrastructure complex the day. But the same softness that emboldened equity bulls — falling payrolls, rising temporary layoffs, downward revisions — rhymes with a mid-2006 macro setup that preceded the 2007 downturn.

A Soft Payrolls Tell Flips the Rate Script — and Tech Runs With It

Three Chokepoints, One Buffer: Why Hormuz, the Black Sea, and the Mecca Pact Are Rewiring Risk Premiums

The Nasdaq Is the Cleanest Tell on a Payroll-Miss Rally

July's -23K payroll miss with 103K in negative revisions is fueling a semiconductor-led Nasdaq rally while cyclicals lag. The market is pricing Fed cuts against a labor market that is actually contracting — a 60/40 trade with real tension underneath.

SpaceX Lockup Tests the Great Equity-Supply Reversal

SpaceX's first lockup expiry could more than double its public float, arriving just as JPMorgan estimates $1.5 trillion in net equity supply over two years. The demand side faces concentration risk from record ETF inflows.